Fuchs P C, Jones R N, Barry A L, Thornsberry C
J Clin Microbiol. 1984 Apr;19(4):555-7. doi: 10.1128/jcm.19.4.555-557.1984.
Disk diffusion susceptibility testing of ticarcillin plus the beta-lactamase inhibitor clavulanic acid was performed on 489 clinical isolates, and the results were compared with reference broth microdilution susceptibilities. Four different disks containing 75 micrograms of ticarcillin plus 2.5, 5, 10, and 15 micrograms of clavulanic acid were evaluated. Based on test performance and clavulanic acid stability, the 75-10-micrograms disk is recommended. Interpretive criteria for ticarcillin as published by the National Committee for Clinical Laboratory Standards appear to be satisfactory for the combination drug, but because the number of ticarcillin-clavulanic acid-resistant isolates was small, this proposal must be considered only tentative.
对489株临床分离株进行了替卡西林加β-内酰胺酶抑制剂克拉维酸的纸片扩散药敏试验,并将结果与参考肉汤微量稀释药敏结果进行比较。评估了四种不同的纸片,分别含75微克替卡西林加2.5、5、10和15微克克拉维酸。基于试验性能和克拉维酸稳定性,推荐使用75-10微克的纸片。美国国家临床实验室标准委员会公布的替卡西林解释标准似乎适用于该联合药物,但由于对替卡西林-克拉维酸耐药的分离株数量较少,该提议只能视为暂定的。